Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Olivier Danos, Frank Witney, John Radak

Premium

Biogen Idec has hired Olivier Danos as senior VP of gene therapy. Danos will report to Douglas Williams, executive VP of R&D at Biogen Idec. At Biogen Idec, he will be in charge of the gene therapy research group, which develops new technologies for gene transfer and genome engineering.

Before joining the firm, Danos was senior VP of molecular medicine, synthetic biology, and gene regulation at Kadmon Pharmaceuticals; directed the Gene Therapy Consortium at the University of London; and led a gene therapy research effort at the Necker Hospital, Enfants Malades in Paris.


Exagen Diagnostics has appointed Frank Witney and John Radak as independent directors, effective September 18. Witney is president and CEO of Affymetrix and Radak is CFO of the biotech product development firm ArborGen Inc.

Simultaneously, Exagen also announced that Samuel Riccitelli and Michael Walsh will no longer serve on its board. That brings the company's board of directors to seven members, six of which are independent directors.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.